Literature DB >> 15094231

Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.

Ramon Planas1, Belén Ballesté, Marco Antonio Alvarez, Monica Rivera, Silvia Montoliu, Josep Anton Galeras, Justiniano Santos, Susanna Coll, Rosa Maria Morillas, Ricard Solà.   

Abstract

BACKGROUND/AIMS: Since few data are available concerning the clinical course of decompensated hepatitis C virus (HCV)-related cirrhosis, the aim of the present study was to define the natural long-term course after the first hepatic decompensation.
METHODS: Cohort of 200 consecutive patients with HCV-related cirrhosis, and without known hepatocellular carcinoma (HCC), hospitalized for the first hepatic decompensation.
RESULTS: Ascites was the most frequent first decompensation (48%), followed by portal hypertensive gastrointestinal bleeding (PHGB) (32.5%), severe bacterial infection (BI) (14.5%) and hepatic encephalopathy (HE) (5%). During follow-up (34+/-2 months) there were 519 readmissions, HCC developed in 33 (16.5%) patients, and death occurred in 85 patients (42.5%). The probability of survival after diagnosis of decompensated cirrhosis was 81.8 and 50.8% at 1 and 5 years, respectively. HE and/or ascites as the first hepatic decompensation, baseline Child-Pugh score, age, and presence of more than one decompensation during follow-up were independently correlated with survival.
CONCLUSIONS: Once decompensated HCV-related cirrhosis was established, patients showed not only a very high frequency of readmissions, but also developed decompensations different from the initial one. These results contribute to defining the natural course and prognosis of decompensated HCV-related cirrhosis.

Entities:  

Mesh:

Year:  2004        PMID: 15094231     DOI: 10.1016/j.jhep.2004.01.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  84 in total

1.  Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort.

Authors:  Kara B Johnson; Emily J Campbell; Heng Chi; Hui Zheng; Lindsay Y King; Ying Wu; Andrew Delemos; Abu Hurairah; Kathleen Corey; James M Richter; Raymond T Chung
Journal:  Dig Dis Sci       Date:  2013-08-30       Impact factor: 3.199

2.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

Review 3.  Gut flora and bacterial translocation in chronic liver disease.

Authors:  John Almeida; Sumedha Galhenage; Jennifer Yu; Jelica Kurtovic; Stephen M Riordan
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

4.  Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease.

Authors:  Kenneth Berman; Sweta Tandra; Kate Forssell; Raj Vuppalanchi; Raj Vuppalanch; James R Burton; James Nguyen; Devonne Mullis; Paul Kwo; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2010-11-17       Impact factor: 11.382

5.  Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.

Authors:  Michele Merli; Carlo Visco; Michele Spina; Stefano Luminari; Virginia Valeria Ferretti; Manuel Gotti; Sara Rattotti; Valeria Fiaccadori; Chiara Rusconi; Clara Targhetta; Caterina Stelitano; Alessandro Levis; Achille Ambrosetti; Davide Rossi; Luigi Rigacci; Alfonso Maria D'Arco; Pellegrino Musto; Annalisa Chiappella; Luca Baldini; Maurizio Bonfichi; Luca Arcaini
Journal:  Haematologica       Date:  2013-11-22       Impact factor: 9.941

6.  Bacteremia and "Endotipsitis" following transjugular intrahepatic portosystemic shunting.

Authors:  Meir Mizrahi; Lilach Roemi; Daniel Shouval; Tomer Adar; Maya Korem; Alon Moses; Alan Bloom; Oren Shibolet
Journal:  World J Hepatol       Date:  2011-05-27

7.  Activation of inactive hepatocytes through histone acetylation: a mechanism for functional compensation after massive loss of hepatocytes.

Authors:  Yujun Shi; Huaiqiang Sun; Ji Bao; Ping Zhou; Jie Zhang; Li Li; Hong Bu
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

8.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

9.  Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins.

Authors:  Giovanni Tarantino; Vincenzo Citro; Pasquale Esposito; Sabrina Giaquinto; Annalisa de Leone; Graziella Milan; Francesca Saveria Tripodi; Michele Cirillo; Roberto Lobello
Journal:  BMC Gastroenterol       Date:  2009-03-17       Impact factor: 3.067

10.  Incisional hernia as an unusual cause of hepatic encephalopathy in a 62-year-old man with cirrhosis: a case report.

Authors:  Muge Ustaoglu; Tulay Bakir; Ahmet Bektas; Osman Cure; Bulent Gungor
Journal:  J Med Case Rep       Date:  2009-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.